Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug

Hyderabad-based drug maker Hetero said on Sunday that it had received approval of regulator Drug Controller General of India (DCGI) to manufacture and market investigational antiviral medicine Remdesivir for the treatment of COVID-19 disease. The company said in a press release that its generic version of US-based Gilead Science's experimental COVID-19 treatment Remdesivir will be marketed under brand name Covifor in India. Covifor w...